Realm Therapeutics to Present at the 5th Annual Dermatology Summit

MALVERN, Pa., Jan. 2, 2018 - Realm Therapeutics plc (AIM: RLM), a clinical stage biopharmaceutical company focused on leveraging its proprietary immunomodulatory technology, is pleased to announce that Alex Martin, CEO, will be presenting at the 5th Annual Dermatology Summit, an Advancing Innovation in Dermatology conference, on Sunday, January 7, 2018 at 2:15 p.m. PT at the Palace Hotel in San Francisco, CA.

An updated copy of Realm's corporate presentation is available on the Company's website at www.realmtx.com.

About Realm Therapeutics

Realm Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel immunomodulatory therapies to protect and improve the lives of adults and children. The Company has initiated drug development programs, based on its proprietary hypochlorous acid technology at high concentrations. The Company believes its formulations have novel immunomodulatory activity with potential application for the treatment of diseases in a number of therapeutic areas, including Dermatology and Ophthalmology.